Michael Cohen of Brown Rudnick LLP is a seasoned attorney specializing in life sciences, venture capital, and emerging companies. With expertise in cross-border transactions, Cohen advises both investors and startups on financing and M&A. Notable matters include leading $175m in Series B financing for Aktis Oncology and assisting MPM BioImpact in a $40m Series A investment for āshibio.
Legal 500 redaktioneller Kommentar
- Profil
Auszeichnungen
Boston Elite
Kernmandanten
- Aktis Oncology, a biotechnology company.
- Crossbow Therapeutics, a biotechnology company.
- MPM BioImpact, a biotechnology investment firm.
Highlight-Mandate
- Represented Aktis Oncology in its oversubscribed $175m Series B financing, led by RA Capital, RTW Investments, and Janus Henderson Investors, continuing its support for the biotech company developing targeted radiopharmaceuticals for solid tumor cancers.
- Led MPM BioImpact in its $40m investment in California-based biotech company āshibio’s Series A funding round, supporting the development of novel therapies, including a potential treatment for fibrodysplasia ossificans progressiva (FOP).
- Represented Crossbow Therapeutics in its $80m Series A financing, led by MPM BioImpact and Pfizer Ventures, to advance the development of novel cancer therapies targeting peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells.